XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

J&J gets $260 million talc verdict overturned in Oregon, new trial ordered



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-J&J gets $260 million talc verdict overturned in Oregon, new trial ordered</title></head><body>

Adds statement from plaintiff's lawyer in paragraph 4

By Brendan Pierson

Sept 16 (Reuters) -A state judge in Oregon has overturned a jury's $260 million verdict against Johnson & Johnson JNJ.N in a lawsuit brought by a woman who said she got mesothelioma, a deadly cancer linked to asbestos exposure, from inhaling the company's talc powder, the company said on Monday.

Judge Katharine von ter Stegge in Portland granted J&J's motion to throw out the verdict and hold a new trial in the case at a hearing late on Friday, according to a spokesperson for the company. Von ter Stegge is expected to issue a written opinion explaining her order in the coming days.

Erik Haas, J&J's worldwide vice president of litigation, said the original verdict was "the direct result of numerous egregious errors committed by the plaintiff's lawyers" and had "no basis in the law or science."

"While we respect the court and its ruling, we also disagree," said Trey Branham, a lawyer for plaintiff Kyung Lee.

Branham said Lee would appeal the judge's decision.

J&J is facing claims by more than 62,000 plaintiffs that its baby powder and other talc products were contaminated with asbestos and caused cancer. Most of the lawsuits involve ovarian and other gynecological cancers, with a small minority over mesothelioma. J&J has said that its talc is safe, does not contain asbestos and does not cause cancer.

Lee, who sued J&J along with her husband, was diagnosed with mesothelioma last year at age 48. She has said she had inhaled asbestos-tainted talc over a period of more than 30 years, beginning when her mother used it on her when she was a baby and later when she used it herself as a deodorant.

A lawyer for J&J said at trial that Lee's illness was likely caused by exposure to asbestos used at a factory near where she grew up.

J&J is preparing to have a subsidiary file bankruptcy in order to settle the ovarian and other gynecological cancer lawsuits for about $9 billion. The company has said it has secured support for the deal from well over 75% of claimants, the legal threshold for a judge to approve the kind of bankruptcy settlement J&J has proposed.

The bankruptcy filing and settlement would not affect mesothelioma cases like Lee's.



Reporting By Brendan Pierson in New York; Editing by Alexia Garamfalvi, Leslie Adler and Will Dunham

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.